Exenatide once weekly in type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1297-1303

  Bischoff, Lindsay A ^a   Jabbour, Serge A ^a   Miller, Jeffrey L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

diabetes mellitus; exenatide; GLP 1; incretin; type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; TASPOGLUTIDE; VILDAGLIPTIN;

ANTIBODY PRODUCTION; ARTICLE; BODY WEIGHT; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE IRRITATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MEDLINE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHARMACODYNAMICS; QT PROLONGATION; THYROID CANCER;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECEPTORS, GLUCAGON; TIME FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 79955789225     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.573145     Document Type: Article

References (38)

1. National Diabetes Statistics, 2007.Available from: http://diabetes.niddk. nih.gov/dm/pubs/statistics [Last accessed 25 January 2011]
2. Baggio LL, Huang Q, Cao X, Drucker DJ.An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.Gastroenterology 2008;134:1137-47 (Pubitemid 351451971)
3. Hui H, Farilla L, Merkel P, Perfetti R.The short half-life of glucagon like peptide-1 in plasma does not reflect its long-lasting beneficial effects.Eur J Endocrinol 2002;146:863-9 (Pubitemid 34705080)
4. Klonoff DC, Buse JB, Nielsen LL, et al.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least three years.Curr Med Res Opin 2008;24:275-86 (Pubitemid 351160260)
5. Amylin Pharmaceuticals, Eli Lilly, and Co.Byetta package insert.Sept 2010
6. Novo Nordisk.Victoza package insert.Jan 2010
7. Garber A, Henry R, Ratner R, et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.Lancet 2009;373:473-81
8. David Joffe.Liraglutide: a once daily human glucagon like peptide-1 analogue for type 2 diabetes mellitus.Am J Health Syst Pharm 2010;67:1326-36
9. Bjerre Knudsen L, Madsen LW, Andersen S, et al.Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.Endocrinology 2010;151:1473-86
10. Chan JC, Scott R, Arjona Ferreira JC, et al.Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.Diabetes Obes Metab 2008;10:545-55 (Pubitemid 351850898)
11. Rosenstock J, Sankoh S, List JF.Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.Diabetes Obes Metab 2008;10:376-86 (Pubitemid 351524285)
12. Gm Keating.Vildagliptin: a review of its use in type 2 diabetes mellitus.Drugs 2010;70:2089-112
13. Amylin Pharmaceuticals.Januvia (sitagliptin) prescribing information.Jan 2011
14. Merck Pharmaceuticals.Onglyza (saxagliptin) prescribing information.revised and published Feb 2011
15. Fact Sheet Medisorb Microspheres Technology, January 2009.Available from: http://www.alkermes.com/media/42408/general%20medisorb% 20techonology%20fact%20sheet%20jan %202009%20-%20011409%20pdf [Last accessed 20 November 2010].
16. Chen YE, Drucker DJ.Tissue-specific expressions of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard.J Biol Chem 1997;272:4108-15 (Pubitemid 27078475)
17. Amylin Pharmaceuticals.Byetta (exenatide) injection prescribing information.Published Sept 2010
18. Kim D, MacConell L, Zhuang D, et al.Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.Diabetes Care 2007;30:1487-93 (Pubitemid 46871159)
19. Gardner DG, Shoback D.Greenspans basic and clinical endocrinology.8th edition.McGraw-Hill; 2007.p.664-5, USA
20. Drucker DJ, Buse JB, Taylor K, et al.; DURATION-1 Study Group.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.Lancet 2008;372:1240-50
21. Iwamoto K, Nasu R, Yamamura A, et al.Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.Endocr J 2009;56:951-62
22. Copley K, McCowen K, Hiles R, et al.Investigation of exenatide elimination and its in vivo and in vitro degredation.Curr Drug Metab 2006;7:367-74
23. Linnebjerg H, Kothare PA, Park S, et al.Effect of renal impairment on the pharmacokinetics of exenatide.Br J Clin Pharmacol 2007;64:317-27 (Pubitemid 47283860)
24. Diamant M, Van Gaal L, Stranks S, et al.Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.Lancet 2010;375:2234-43
25. Buse JB, Drucker DJ, Taylor KL, et al.; DURATION-1 Study Group.DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.Diabetes Care 2010;33:1255-61
26. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group.Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.Lancet 2010;376:431-9
27. Wysham C, Bergenstal R, Malloy J, et al.DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.Diabet Med 22 Mar 2011 [Epub ahead of print]
28. Amylin Pharmaceuticals.DURATION-4: study results: BYDUREON efficacy and tolerability profile extended to monotherapy treatment.Press release.Available from: http://investors.amylin.com/phoenix.zhtml?c=101911&p= irolnewsArticle&ID=1438147&highlight=) [Last accessed 24 January 2011]
29. Fineman MS, Biscak TA, Shen LZ, et al.Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.Diabetes Care 2003;26:2370-7 (Pubitemid 36993328)
30. Buse JB, Montanya E, Sesti G, et al.The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison [abstract 857-P].Presented at the 46th Annual Meeting of the European Association for the Study of Diabetes, 20 - 24 September 2010, Stockholm, Sweden.
31. Investor Update.18 June 2010.Available from: http://www.roche.com/ investors/ir-update [Last accessed 6 March 2011]
32. Blevins T, Pullman J, Malloy J, et al.DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.J Clin Endocrinol Metab 9 Feb 2011 [Epub ahead of print]
33. Raskin P, Mohan A.Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial).Expert Opin Pharmacother 2010;11:2269-71
34. Dore DD, Seeger JD, Arnold CK.Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.Curr Med Res Opin 2009;25:1019-27
35. Bloomgren G, Dore D, Wenton M, et al.Incidence and relative incidence of medical record confirmed acute pancreatitis: exenatide initiators compared to other antidiabetic drug initiators [abstract 543-P].Presented at the American Diabetes Association 70th Scientific Sessions, 25 - 29 June 2010, Orlando, Florida, USA.
36. Wenten M, Gaebler J, Hussein M, et al.A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other antidiabetic medication: a follow up study [abstract 596-P].Presented at the American Diabetes Association 70th Scientific Sessions, 25 - 29 June 2010, Orlando, Florida, USA.
37. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.October 2005.
38. Linnebjerg H, Seger M, Kothare P, et al.The effects of exenatide on QTc interval in healthy subjects [abstract 597-P].Presented at the American Diabetes Association 70th Scientific Sessions, 25 - 29 June 2010, Orlando, Florida, USA.